Treatment of Cholesterol Abnormalities
Am Fam Physician. 2005 Mar 15;71(6):1137-1142.
This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). EB CME is clinical content presented with practice recommendations supported by evidence that has been systematically reviewed by an AAFP-approved source.
Cardiovascular disease and its subset coronary heart disease are leading causes of morbidity and mortality in the United States and world wide. In general, higher levels of low-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease, myocardial infarction, and stroke. Reducing dietary fat can improve total cholesterol levels, but consequent reductions in cardiovascular outcomes are not well documented. The Mediterranean diet is the only dietary intervention associated with a reduction in all-cause mortality. Treatment with cholesterol-lowering medications decreases the rate of cardiovascular events, but a reduction in all-cause mortality with these agents has been found only in patients with pre-existing coronary heart disease. Drug treatment in patients with a history of heart disease and average-to-high cholesterol levels can decrease the risk for stroke. In patients with peripheral vascular disease, treatment of elevated cholesterol levels may slow disease progression.
Coronary heart disease (CHD) is the single leading cause of death in the United States, accounting for more than one in five deaths each year, or approximately 500,000 fatalities. An estimated $130 billion was spent in 2003 to care for patients with CHD, and an estimated $7.2 billion of this cost was spent on drug therapy.1
The 2001 report of the National Cholesterol Education Program (NCEP)2 expert panel estimates that therapeutic lifestyle changes should be recommended for 65 million U.S. adults and that 36 million of those persons also need drug therapy for treatment of elevated cholesterol levels. The relationship between CHD and elevated cholesterol levels has been recognized for many years, but only since the mid-1990s have studies shown an improvement in patient-oriented outcomes in patients receiving drug therapy (e.g., myocardial infarction [MI] or mortality, rather than just changes in cholesterol levels).
Current expert-based guidelines have attempted to translate these findings to specific targets for patient cholesterol levels.2 A patient’s baseline risk for CHD is an important determinant of the degree of benefit; treatment clearly has a greater impact in patients with a greater risk. Applying the evidence to lower risk populations is difficult because many more patients need to be treated to achieve benefit. Most of the demonstrated benefit in lower risk populations relates only to disease-specific outcomes (i.e., no improvement in all-cause mortality). A 2001 study3 reviewing the four largest primary-prevention trials at the time found that up to 40 percent of men and 80 percent of women would not have met eligibility criteria. For example, persons with low total cholesterol levels but low high-density lipoprotein (HDL) cholesterol levels, or those with average total cholesterol levels and average-to-high levels of HDL cholesterol had not been studied.
Primary Prevention of Cardiovascular Disease
To address the efficacy of lifestyle interventions recommended by the NCEP and American Heart Association, a systematic review4 of 18 trials with a total of 140,000 patients found modest reductions in blood cholesterol levels and smoking prevalence but no change in all-cause or cardiovascular mortality in patients who received counseling interventions targeting dietary habits, smoking, and physical activity. Another systematic review5 of 27 randomized controlled trials (RCTs) looked at reducing the intake of overall fat and saturated fats during 30,000 person-years. It found a small reduction in cardiovascular events. The benefit was noted in higher risk patients who maintained their lifestyle changes for at least two years.
|Key clinical recommendation||Label||References|
Primary prevention of cardiovascular disease
Patients with elevated cholesterol levels should reduce dietary fat consumption. However, this step may lead to only a small reduction in cardiovascular events.
Statin medications are indicated to decrease cardiovascular events in patients with elevated cholesterol levels, although a decrease in cardiovascular and all-cause mortality has not been demonstrated.
Following a Mediterranean diet may reduce all-cause mortality.
Secondary prevention of cardiovascular disease
Statin medications should be used for aggressive lipid control in patients with CHD to decrease cardiovascular events, cardiovascular mortality, and overall mortality.
Cholesterol-lowering medications prevent disease progression and improve symptoms in patients with lower limb atherosclerosis. Statins can decrease cardiovascular events and all-cause mortality in these patients.
Cholesterol-lowering medications should be used to reduce the risk of stroke in patients with a history of CHD and average-to-high cholesterol levels.
CHD = coronary heart disease.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1046 for more information.
Dietary advice leads to an average 3 to 6 percent decrease in total cholesterol levels.6 A recent large prospective study7 in Greece found an association between adherence to a Mediterranean diet and lower all-cause mortality. This benefit was greater in older, heavier, sedentary nonsmokers.
The use of cholesterol-lowering drugs for primary prevention of heart disease initially was a matter of controversy. The first study to show clear improvement in patient-oriented outcomes in a primary-prevention population using cholesterol-lowering medications found a decreased incidence of nonfatal MI and CHD deaths in patients with elevated cholesterol levels who were treated with pravastatin.8 More recently, large systematic reviews reached similar conclusions about the use of cholesterol-lowering medications for the primary prevention of CHD. A review9 of 23 trials in which patients were treated with statin drugs found a significant reduction in nonfatal MI, but the primary-prevention trials were underpowered to detect effects on mortality. A meta-analysis10 of four primary-prevention studies with 10,000 patients who had elevated cholesterol levels found a lower incidence of cardiovascular events and reduced cholesterol levels (8 percent with cholestyramine, 10 percent with gemfibrozil, and 20 percent with statins), but no reduction in overall or cardiovascular mortality. This means that 60 patients need five years of treatment to prevent one coronary artery disease (CAD) event.
Similarly, lovastatin reduces the risk for first coronary events but not all-cause mortality when used for primary prevention in patients with low HDL cholesterol levels but average total cholesterol levels (number needed to treat [NNT], 24).11 Interestingly, smokers taking lovastatin had outcomes similar to outcomes in nonsmokers taking placebo, which strongly suggests the relative cost effectiveness of smoking cessation. A recent study12 of simvastatin in more than 20,000 compliant, high-risk, primary-prevention patients found a decreased risk of major coronary events, revascularizations, and stroke (risk decreased from 25 to 20 percent; NNT, 21).
Finally, the Anglo-Scandinavian Cardiac Outcomes Trial13 found reductions in major cardiovascular events in a high-risk (average 3.7 risk factors) primary-prevention population treated with atorvastatin. Similarly, low-dosage atorvastatin delays the development of cardiovascular events in diabetic patients who are treated with a 10-mg dose.14 These studies also suggest that the benefit of drug interventions increases with increasing baseline risk. This suggestion is reflected in the British Medical Journal (BMJ) Clinical Evidence group’s conclusion that for primary prevention of coronary events, “reducing cholesterol concentration in asymptomatic people lowers the rate of cardiovascular events,”15 but not cardiovascular or overall mortality.
One approach to further risk stratification of patients for primary prevention may include assessment of the C-reactive protein (CRP) level, which appears to be an independent predictor of cardiovascular risk.16 However, only preliminary evidence shows that healthy patients with high CRP levels and low or normal cholesterol levels could benefit from drug treatment.
Ezetimibe, an agent introduced in 2002, blocks the absorption of cholesterol from the intestine. A recent RCT17 found that therapy with 10 mg of ezetimibe plus 10 mg of atorvastatin had effects on lipid levels similar to the effects of therapy with 80 mg of atorvastatin alone. However, no outcome data are available for CAD events, cardiovascular mortality, or total mortality.
SAFETY OF CHOLESTEROL-LOWERING DRUGS
Because cholesterol-lowering drugs have been shown to affect cardiovascular mortality more than total mortality, concern has arisen that these agents might increase mortality from other causes. A meta-analysis18 of 19 RCTs found no increase in noncardiovascular disease mortality in patients taking cholesterol-lowering drugs. This finding was most convincing in patients taking statins; there was a trend toward increased deaths and violence in the dietary and non-statin–drug groups.
HERBAL SUPPLEMENTS FOR CHD PREVENTION
Garlic consumption appears to result in moderate decreases in cholesterol levels,19 and weaker evidence indicates that the same may be true for red yeast rice, soy,20 artichoke,21 fenugreek, and guggul,22 although a recent study23 found that guggulipid was not effective and had significant side effects. A small crossover RCT24 found that healthy hyperlipidemic patients on a low-fat diet reduced cholesterol levels by an additional 4 to 5 percent with a diet high in soluble fiber (e.g., barley, beans, oat bran, psyllium). A meta-analysis25 of 67 RCTs estimated that 3 g of soluble fiber from oats can decrease total and low-density lipoprotein (LDL) cholesterol by 5 mg per dL (0.15 mmol per L). Unfortunately, none of the studies evaluating dietary and herbal interventions looked at patient-oriented outcomes.
Secondary Prevention of Cardiovascular Disease
The 1994 Scandinavian Simvastatin Survival Study26 found lower mortality rates (absolute risk decreased from 11.5 to 8.2 percent; NNT, 30) and fewer coronary events (NNT, 15) in patients with angina or acute MI who were treated with simvastatin to a total cholesterol target of less than 200 mg per dL (5.20 mmol per L). Subsequent RCTs and systematic reviews have strongly confirmed the benefits of cholesterol treatment in this population. A systematic review27 of seven RCTs of high-risk diabetic patients found that medications to lower cholesterol in patients with a history of cardiovascular disease substantially reduced cardiovascular disease. The BMJ Clinical Evidence group concludes that for secondary prevention, “lowering cholesterol … substantially reduces overall mortality, cardiovascular mortality, and non-fatal cardiovascular events.”15 Of current drug treatments, statins appear to have the greatest effect on outcomes. A large systematic review28 that included 66 RCTs found that statins decreased overall mortality and CAD mortality. Bile-acid resins had a borderline effect on CAD mortality, but the use of resins and other medications (i.e., resins, niacin, fibrates, and hormones combined) showed a trend toward higher all-cause mortality. The Women’s Health Initiative found an increase in adverse cardiovascular outcomes in women taking hormone therapy. Niacin fell short of statistical significance for improving cardiovascular outcomes in a 1996 review29 of 23 secondary-prevention trials. In another study,30 gemfibrozil reduced the risk of cardiovascular events in men with CAD, normal LDL levels, and low HDL levels, but this study did not address overall mortality.
A recent large RCT31 involving 20,000 high-risk patients found reductions in all-cause mortality, vascular mortality, major CAD events, and stroke in patients who took simvastatin. In an RCT32 of 9,000 patients, pravastatin reduced all-cause mortality (11.0 versus 14.1 percent; NNT, 34 for six years) and cardiovascular mortality. Elderly patients may derive more benefit from pravastatin treatment than younger patients.33,34 In the large Cholesterol and Recurrent Events (CARE) RCT,35 the benefits of secondary prevention extended to patients with average cholesterol levels, although all-cause mortality was not studied.
Lovastatin decreased rates of major cardiovascular events and overall mortality rates in high-risk patients with asymptomatic carotid stenosis.36 Rosuvastatin has a greater effect on lipid profiles than other available statins, but there currently are no outcome studies. Atorvastatin also has a marked effect on lipid profiles.37 It has not yet been proved to decrease mortality in an ambulatory population but is at least as effective as percutaneous transluminal coronary angioplasty in reducing the rate of ischemic events in patients with stable CAD.38 High-dosage atorvastatin39 and high-dosage simvastatin40 also reduce recurrent ischemic events in hospitalized patients with acute coronary syndrome, and atorvastatin decreases coronary atheroma burden in CAD patients as measured by intravascular ultrasonography. Intensive lipid-lowering therapy has not been shown to decrease cardiovascular events or mortality in patients without acute coronary syndrome, and current guidelines should continue to be used as treatment goals until larger ongoing trials are completed.41,42
The difficulty of generalizing results of statin studies to a class effect is illustrated by the recent withdrawal of cerivastatin, but not other statins, from the market because of adverse effects. In addition, a review43 of the pharmacology of the various agents concluded that there may be important clinical differences between individual statins, including “subtle differences in nonlipid effects” that may lead to clinically important differences in efficacy as well as safety.
Overall, statins seem to have the greatest effect of all cholesterol-lowering medications on the reduction of cardiovascular and all-cause mortality.28 However, their high cost per life-year gained (estimated at $2,500 to $6,000) places them behind aspirin ($25), advice for smoking cessation, diuretics in elderly patients with hypertension ($20), beta blockers following MI ($150), and the Mediterranean diet following MI ($150) in cost effectiveness.9 As with primary prevention, cost effectiveness is better in groups with higher baseline risk.44
Prevention and Treatment of Stroke
Cholesterol-lowering medications reduce the risk of stroke in patients with CHD and average or high cholesterol levels, but not in patients with previous stroke or transient ischemic attack (TIA). The 2001 Veterans Affairs HDL Intervention Trial45 found that men with documented CHD and low HDL levels lowered their risk of stroke by taking gemfibrozil. The 1999 CARE trial35 found that pravastatin decreased the risk of stroke in 65- to 75-year-old patients with a history of MI and average cholesterol levels. A meta-analysis46 of a mixed primary- and secondary-prevention population of 29,000 patients found an absolute risk reduction for stroke of 0.5 percent in patients treated with statins. A 1999 review47 of 13 RCTs of almost 20,000 statin-treated patients with LDL levels greater than 155 mg per dL (4.00 mmol per L) found a decreased incidence of stroke in patients with documented CHD or at least two additional risk factors (NNT, 143 to prevent one stroke in four years), but stroke incidence was unchanged in the primary-prevention studies.
Simvastatin reduced the rate of stroke in compliant patients at high risk for CHD or with known CHD (NNT, 72 for 4.3 years), but not in patients with known cerebrovascular disease.48 A Cochrane review49 of five studies with 1,700 patients showed no evidence of benefit or harm in patients with a history of stroke or TIA but no history of CHD.
Treatment of Peripheral Vascular Disease
A recent Cochrane review50 of seven trials involving 698 men and women showed that lipid-lowering therapy with a variety of drugs reduced disease progression as measured by angiography and somewhat improved claudication symptoms. When peripheral vascular disease is used as a marker for high risk of cardiovascular events, treatment of these patients with simvastatin results in lower mortality, fewer major coronary events, lower stroke rates, and revascularizations without increasing nonvascular mortality.31
1. American Heart Association. Heart disease and stroke statistics update. Accessed online December 16, 2004, at: http://www.americanheart.org/presenter.jhtml?identifier=1928.
2. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Accessed online December 16, 2004, at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
3. Lloyd-Jones DM, O’Donnell CJ, D’Agostino RB, Massaro J, Silbershatz H, Wilson PW. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Arch Intern Med. 2001;161:949–54.
4. Ebrahim S, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2000;(2):CD001561.
5. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev. 2001;(3):CD002137.
6. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ. 1998;316:1213–20.
7. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348:2599–608.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.
9. Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, et al. What role for statins? A review and economic model. Health Technol Assess. 1999;3:i–iv,1–91.
10. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321:983–6.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
14. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early invasive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–16.
15. Foster C, Murphy M, Nicholas JJ, Pignone M, Bazian Ltd. Cardiovascular disorders. Primary prevention. Accessed online December 16, 2004, at: http://www.clinicalevidence.com/ceweb/conditions/cvd/0205/0205_Q3.jsp.
16. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.
17. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hyper-cholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–15.
18. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ. 2001;322:11–5.
19. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420–9.
20. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276–82.
21. Pittler MH, Thompson CO, Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev. 2002;(3):CD003335.
22. Thompson Coon JS, Ernst E. Herbs for serum cholesterol reduction: a systematic view. J Fam Pract. 2003;52:468–78.
23. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, Der-Marderosian AH, Cirigliano MD, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765–72.
24. Jenkins DJ, Wolever TM, Rao AV, Hegele RA, Mitchell SJ, Ransom TP, et al. Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N Engl J Med. 1993;329:21–6.
25. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30–42.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
27. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med. 2001;111:633–42.
28. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999;19:187–95.
29. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by anti-dyslipidemic therapy. J Fam Pract. 1996;42:577–86.
30. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.
33. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931–40.
34. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.
35. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681–9.
36. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679–87.
37. Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother. 1998;32:1030–43.
38. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70–6.
39. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.
40. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.
41. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.
42. Sacks FM. High-intensity statin treatment for coronary heart disease. JAMA. 2004;291:1132–4.
43. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother. 2002;36:1907–17.
44. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996;312:1443–8.
45. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828–33.
46. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313–21.
47. Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med. 1999;14:763–74.
48. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–67.
49. Manktelow B, Gillies C, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev. 2002;(3):CD002091.
50. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev. 2004;(3):CD000123.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
More in AFP: